BAFNAPH — Bafna Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- IN₹2.05bn
- IN₹2.14bn
- IN₹1.15bn
- 35
- 41
- 34
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.49 | ||
| Price to Tang. Book | 2.57 | ||
| Price to Free Cashflow | 20.94 | ||
| Price to Sales | 1.34 | ||
| EV to EBITDA | 13.22 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.07% | ||
| Return on Equity | 15.2% | ||
| Operating Margin | 7.13% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 436.27 | 424.73 | 712.18 | 851.4 | 1,154.49 | n/a | n/a | 19.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +25.83 | +54.35 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Company’s subsidiary is Bafna Lifestyles Remedies Limited.
Directors
- Mahaveer Bafna CHM
- Jitendra Pal CCO
- Shanmugam Hemalatha EDR
- Ravichandran Chitra NED
- Atul Sachdeva NED
- R. Dwarakanathan NID (77)
- Babulal Kumar NID
- Akilapriya Raju NID
- Palamadai Sundaresan NID (64)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 28th, 1995
- Public Since
- June 27th, 2008
- No. of Shareholders
- 7,227
- No. of Employees
- 588
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 23,656,335
- Address
- Bafna Towers, 299, Thambu Chetty street, CHENNAI, 600001
- Web
- http://www.bafnapharma.com/
- Phone
- +91 4442677555
- Auditors
- Brahmayya & Co.
Upcoming Events for BAFNAPH
Q1 2025 Bafna Pharmaceuticals Ltd Earnings Release
Bafna Pharmaceuticals Ltd Annual Shareholders Meeting
Similar to BAFNAPH
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Bafna Pharmaceuticals share price?
As of Today at 19:03 UTC, shares in Bafna Pharmaceuticals are trading at IN₹86.80. This share price information is delayed by 15 minutes.
How has the Bafna Pharmaceuticals share price performed this year?
Shares in Bafna Pharmaceuticals last closed at IN₹86.80 and the price had moved by +3.27% over the past 365 days. In terms of relative price strength the Bafna Pharmaceuticals share price has underperformed the S&P BSE 100 Index by -19.9% over the past year.
What are the analyst and broker recommendations for Bafna Pharmaceuticals?
There is no consensus recommendation for this security.
What is the Bafna Pharmaceuticals dividend yield?
Bafna Pharmaceuticals does not currently pay a dividend.
Does Bafna Pharmaceuticals pay a dividend?
Bafna Pharmaceuticals does not currently pay a dividend.
When does Bafna Pharmaceuticals next pay dividends?
Bafna Pharmaceuticals does not currently pay a dividend.
How do I buy Bafna Pharmaceuticals shares?
To buy shares in Bafna Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bafna Pharmaceuticals?
As of the previous close price of IN₹86.80, shares in Bafna Pharmaceuticals had a market capitalisation of IN₹2.05bn.
Where are Bafna Pharmaceuticals shares listed?
Here are the trading details for Bafna Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: BAFNAPH
What kind of share is Bafna Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Bafna Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bafna Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Bafna Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bafna Pharmaceuticals. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -14.89%.
As of the last closing price of IN₹86.80, shares in Bafna Pharmaceuticals were trading -5.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bafna Pharmaceuticals PE Ratio?
The Bafna Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹86.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bafna Pharmaceuticals?
Bafna Pharmaceuticals' management team is headed by:
- Mahaveer Bafna - CHM
- Jitendra Pal - CCO
- Shanmugam Hemalatha - EDR
- Ravichandran Chitra - NED
- Atul Sachdeva - NED
- R. Dwarakanathan - NID
- Babulal Kumar - NID
- Akilapriya Raju - NID
- Palamadai Sundaresan - NID